Glucose-nonfermenting gram-negative rods are becoming increasingly important as opportunistic pathogens in patients receiving antibiotics, chemotherapy, or steroids or with otherwise impaired natural defense mechanisms. The nonfermenters are often resistant to antimicrobial therapy and, therefore, pose a threat as potential agents of serious nosocomial infections. For these reasons it is important that nonfermenters are quickly and accurately identified. These organisms are often slow growers and are relatively inert biochemically, and thus, identification schemes require prolonged incubation with special media. Identifications are therefore timeconsuming and cumbersome. Within the last decade several commercial microsystems have become available for the identification of the nonfermenters. These systems, compared with the conventional methodology, allow for easy storage, inoculation, and interpretation of results, a decreased amount of time needed for quality control, and a more standardized product with a greater correlation of results from laboratory to laboratory. Many laboratories therefore rely entirely upon manual systems for the identification of nonfermenting organisms with little or no use of conventional methodologies.
The AutoMicrobic system (AMS; Vitek Systems, Inc., Hazelwood, Mo.) is a recently available automated system. In addition to the same advantages of manual systems, the AMS has automated the inoculation of the biochemical tests, the reading of the tests, the interpretation of the biochemical patterns, and the printing of a hard copy containing the final organism identification, which results in a significant savings in technologist time. The AMS has been evaluated for its efficiency in (i) screening urines for the enumeration and identification of certain microorganisms (1, 9, 13, 17, 18) , (ii) identifying members of the family Enterobacteriaceae (7, 8, 11) , and (iii) performing susceptibility testing (10) . The AMS now has the capacity to identify seven glucose-nonfermenting rods: Pseudomonas aeruginosa, P. cepacia, P. fluorescens, P. putida, P. maltophilia, and Acinetobacter calcoaceticus (saccharolytic and non-saccharolytic). This study was designed to evaluate this capability of the AMS. (Table 3) , and it was found that the same misidentifications occurred in at least one-half of the repeat trials. The majority of the incorrect identifications were with isolates of P. maltophilia and A. (Table 5 ). All organisms that were misidentified as P. cepacia were susceptible to polymyxin B, whereas P. cepacia is resistant to polymyxin B (6, 12) . Therefore a correlation of the AMS identification of P. cepacia with the polymyxin susceptibility would aid in the detection of some of the AMS misidentifications. AMS identifications were accompanied by the probability of correct identification as based upon biochemical profiles of isolates in the data base. To examine the correlation between the AMS identifications and the identification probabilities, the number of correct and incorrect responses for 472 isolates was compared with the identification probabilities ( Table 6 ). The data showed that at a correct identification probability of -95%, 99.3% of the correct responses were detected. When lowering the probability to 90%, one additional isolate was correctly identified, and three more were misidentified. Similar numbers were seen when the probability interval was 80 to 89%. When a correct identification probability of less than 80% was used, there was 7 6 a Correct identification = "unidentified organism." Of the total of 62 isolates not included in the AMS identification profile, 41 (66.1%) were correctly identified.
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that there was no advantage to using an acceptable identification probability of lower than 95%, since a lower percent probability resulted in a greater incidence of incorrect responses. Retrospective analysis of the AMS identification data was performed with an acceptable identification probability of .95%. AMS identifications were placed into four categories: (i) the correct identification with a probability of .95%, (ii) an incorrect identification with a probability of .95%, (iii) an identification with a probability of less than 95%, or (iv) an "unidentified organism" response ( Table 7) . The accuracy of the AMS in the correct identification of the organisms was 88.5% (category i), and 4.1% of the isolates were misidentified (category ii). The remaining 7.4% of the isolates did not meet the criteria for a reportable identification, either by having an identification probability of less than 95% (category iii) or by being reported as "unidentified organism" (category iv). These responses would not be considered incorrect identifications but would require additional testing for complete identification.
Manual commercial systems for the identification of the nonfermenters (e.g., API 20E, N/F system, Minitek [BBL Microbiology Systems], and Oxi/Ferm [Roche Diagnostics, Div. Hoffmann-La Roche Inc., Nutley, N.J.]) have been evaluated by several workers (2-4, 15, 16, 19) . Some of the systems have been reported to have an accuracy of less than 80% for the identification of the nonfermenters, which indicates that no system is entirely reliable. The evaluations often have not included representative numbers of organisms frequently encountered in the clinical laboratory. The AMS with the EBC+ card has been designed to identify only those nonfermenters commonly encountered in the routine microbiology laboratory (5, 14) . This study has In summary, the AMS provides a rapid and accurate means of identifying the majority of glucose-nonfermenting gram-negative rods isolated from clinical specimens. The short turnaround time and the decreased amount of technologist time required for identification of not only the nonfermenters but also members of the family Enterobacteriaceae make the AMS EBC+ a useful adjunct to the microbiology laboratory. The AMS is easy to integrate into the work flow of the clinical laboratory, especially the laboratory which is operational for more than one shift per day. The AMS also allows for same-day reporting of many results which may be important in the critical care institution. The additional capabilities of the AMS (yeast identification, susceptibility testing, and urine screening) may influence the decision for use of the AMS in the clinical laboratory.
